نتایج جستجو برای: sglt2 inhibitor

تعداد نتایج: 211924  

2017
Naoto Katakami Tomoya Mita Hidenori Yoshii Toshihiko Shiraiwa Tetsuyuki Yasuda Yosuke Okada Yutaka Umayahara Hideaki Kaneto Takeshi Osonoi Tsunehiko Yamamoto Nobuichi Kuribayashi Kazuhisa Maeda Hiroki Yokoyama Keisuke Kosugi Kentaro Ohtoshi Isao Hayashi Satoru Sumitani Mamiko Tsugawa Makoto Ohashi Hideki Taki Tadashi Nakamura Satoshi Kawashima Yasunori Sato Hirotaka Watada Iichiro Shimomura

INTRODUCTION Sodium-glucose co-transporter-2 (SGLT2) inhibitors are anti-diabetic agents that improve glycemic control with a low risk of hypoglycemia and ameliorate a variety of cardiovascular risk factors. The aim of the ongoing study described herein is to investigate the preventive effects of tofogliflozin, a potent and selective SGLT2 inhibitor, on the progression of atherosclerosis in sub...

Journal: :Journal of Pakistan Medical Association 2021

Dapagliflozin is the first novel SGLT2 inhibitor for treatment of Type 2 diabetes. The aim this study was to evaluate its effectiveness and safety in a real-life clinical setting. We analyze data from four hospitals on patients initiated dapagliflozin. HbA1c, weight daily insulin dosage recorded at baseline 6 months follow-up.229 received At baseline, mean HbA1c 82mmol/mol(186) 102 kg(n=159).Th...

Journal: :Clinical journal of the American Society of Nephrology : CJASN 2010
René Santer Joaquim Calado

Four members of two glucose transporter families, SGLT1, SGLT2, GLUT1, and GLUT2, are differentially expressed in the kidney, and three of them have been shown to be necessary for normal glucose resorption from the glomerular filtrate. Mutations in SGLT1 are associated with glucose-galactose malabsorption, SGLT2 with familial renal glucosuria (FRG), and GLUT2 with Fanconi-Bickel syndrome. Patie...

Journal: :European Journal of Heart Failure 2021

Foundational therapy for heart failure and a reduced ejection fraction consists of combination an angiotensin receptor–neprilysin inhibitor, beta-blocker, mineralocorticoid receptor antagonist sodium–glucose co-transporter 2 (SGLT2) inhibitor. However, the conventional approach to implementation is based on historically-driven sequence that not strongly evidence-based, typically requires ?6 mon...

Journal: :American journal of physiology. Renal physiology 2014
Alan M Weinstein

PHYSIOLOGICAL INTEREST IN RENAL glucose handling dates to the era of whole organ experiments, with the description of a renal glucose threshold (Tm) and osmotic diuresis (22). Micropuncture identified the proximal tubule as the locus of glucose reabsorption (3), and brush border vesicle preparations (1, 8) and cellular electrophysiology (4, 18) established the Na dependence of that luminal gluc...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید